EBS News and Press, Emergent Biosolutions Inc. From 06/11/20

Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) --...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Gainers:  Chesapeake Energy (NYSE: CHK )  +140% . More news on: Chesapeake Energy Corporation, Valaris plc, RigNet, Inc., Stocks on the move, , Read more ...

Opiant Pharmaceuticals (NASDAQ: OPNT )  -32%  after Teva prevails in Narcan patent dispute . More news on: Opiant Pharmaceuticals, Inc., Ascena Retail Group, Inc., Ekso Bionics Holdings, Inc., Stocks on the move, , Read more ...

GAITHERSBURG, Md., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN ® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmac...

Emergent BioSolutions (NYSE: EBS ) is 17.5% lower postmarket after the disclosure of a pair of insiders selling stock. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Stocks on the move, Read more ...

Coronavirus vaccine development in the U.S. is about to shift into a higher gear. Emergent BioSolutions (NYSE: EBS) , a company that helps the federal government prepare for potential public health threats, received a task order from Uncle Sam valued at around $628 million for the rapid produ...

Emergent BioSolutions (NYSE: EBS ) has been issued a task order , valued at ~$628M, under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to supp...

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021   Emergent will provide molecule-to-market CDMO services and commit manufacturing capac...

The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19 . And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs. Some investors could be temp...